Selected research
Industry Research
Antitumor ADC Drugs Industry Research Report 2026
Market perspective
The global Antitumor ADC Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antitumor ADC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antitumor ADC Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antitumor ADC Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antitumor ADC Drugs include ADC Therapeutics, Daiichi Sankyo, Genmab, Immunomedics, Rakuten Medical, Seattle Medical Associates, GSK, Roche and RemeGen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antitumor ADC Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antitumor ADC Drugs Market by Company
ADC Therapeutics
Daiichi Sankyo
Genmab
Immunomedics
Rakuten Medical
Seattle Medical Associates
GSK
Roche
RemeGen
Antitumor ADC Drugs Segment by Type
DNA Damaging Drugs
Tubulin Inhibitors
Antitumor ADC Drugs Segment by Application
Breast Cancer
Lymphoma
Other
Antitumor ADC Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antitumor ADC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antitumor ADC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antitumor ADC Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antitumor ADC Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antitumor ADC Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antitumor ADC Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DNA Damaging Drugs
- Tubulin Inhibitors
Applications
- Breast Cancer
- Lymphoma
- Other
Companies covered
- ADC Therapeutics
- Daiichi Sankyo
- Genmab
- Immunomedics
- Rakuten Medical
- Seattle Medical Associates
- GSK
- Roche
- RemeGen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antitumor ADC Drugs Market Size (2021-2032)
- 2.2.2 Global Antitumor ADC Drugs Sales (2021-2032)
- 2.2.3 Global Antitumor ADC Drugs Market Average Price (2021-2032)
- 2.3 Antitumor ADC Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 DNA Damaging Drugs
- 2.3.3 Tubulin Inhibitors
- 2.4 Antitumor ADC Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Lymphoma
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antitumor ADC Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antitumor ADC Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antitumor ADC Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Antitumor ADC Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Antitumor ADC Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antitumor ADC Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antitumor ADC Drugs, Product Type & Application
- 3.8 Global Manufacturers of Antitumor ADC Drugs, Established Date
- 3.9 Global Antitumor ADC Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ADC Therapeutics
- 4.1.1 ADC Therapeutics Company Information
- 4.1.2 ADC Therapeutics Business Overview
- 4.1.3 ADC Therapeutics Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ADC Therapeutics Antitumor ADC Drugs Product Portfolio
- 4.1.5 ADC Therapeutics Recent Developments
- 4.2 Daiichi Sankyo
- 4.2.1 Daiichi Sankyo Company Information
- 4.2.2 Daiichi Sankyo Business Overview
- 4.2.3 Daiichi Sankyo Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Daiichi Sankyo Antitumor ADC Drugs Product Portfolio
- 4.2.5 Daiichi Sankyo Recent Developments
- 4.3 Genmab
- 4.3.1 Genmab Company Information
- 4.3.2 Genmab Business Overview
- 4.3.3 Genmab Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Genmab Antitumor ADC Drugs Product Portfolio
- 4.3.5 Genmab Recent Developments
- 4.4 Immunomedics
- 4.4.1 Immunomedics Company Information
- 4.4.2 Immunomedics Business Overview
- 4.4.3 Immunomedics Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Immunomedics Antitumor ADC Drugs Product Portfolio
- 4.4.5 Immunomedics Recent Developments
- 4.5 Rakuten Medical
- 4.5.1 Rakuten Medical Company Information
- 4.5.2 Rakuten Medical Business Overview
- 4.5.3 Rakuten Medical Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Rakuten Medical Antitumor ADC Drugs Product Portfolio
- 4.5.5 Rakuten Medical Recent Developments
- 4.6 Seattle Medical Associates
- 4.6.1 Seattle Medical Associates Company Information
- 4.6.2 Seattle Medical Associates Business Overview
- 4.6.3 Seattle Medical Associates Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Seattle Medical Associates Antitumor ADC Drugs Product Portfolio
- 4.6.5 Seattle Medical Associates Recent Developments
- 4.7 GSK
- 4.7.1 GSK Company Information
- 4.7.2 GSK Business Overview
- 4.7.3 GSK Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GSK Antitumor ADC Drugs Product Portfolio
- 4.7.5 GSK Recent Developments
- 4.8 Roche
- 4.8.1 Roche Company Information
- 4.8.2 Roche Business Overview
- 4.8.3 Roche Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Antitumor ADC Drugs Product Portfolio
- 4.8.5 Roche Recent Developments
- 4.9 RemeGen
- 4.9.1 RemeGen Company Information
- 4.9.2 RemeGen Business Overview
- 4.9.3 RemeGen Antitumor ADC Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 RemeGen Antitumor ADC Drugs Product Portfolio
- 4.9.5 RemeGen Recent Developments
5 Global Antitumor ADC Drugs Market Scenario by Region
- 5.1 Global Antitumor ADC Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antitumor ADC Drugs Sales by Region: 2021-2032
- 5.2.1 Global Antitumor ADC Drugs Sales by Region: 2021-2026
- 5.2.2 Global Antitumor ADC Drugs Sales by Region: 2027-2032
- 5.3 Global Antitumor ADC Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Antitumor ADC Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Antitumor ADC Drugs Revenue by Region: 2027-2032
- 5.4 North America Antitumor ADC Drugs Market Facts & Figures by Country
- 5.4.1 North America Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antitumor ADC Drugs Sales by Country (2021-2032)
- 5.4.3 North America Antitumor ADC Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antitumor ADC Drugs Market Facts & Figures by Country
- 5.5.1 Europe Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antitumor ADC Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Antitumor ADC Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antitumor ADC Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antitumor ADC Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antitumor ADC Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antitumor ADC Drugs Market Facts & Figures by Country
- 5.7.1 South America Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antitumor ADC Drugs Sales by Country (2021-2032)
- 5.7.3 South America Antitumor ADC Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antitumor ADC Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antitumor ADC Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antitumor ADC Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antitumor ADC Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antitumor ADC Drugs Sales by Type (2021-2032)
- 6.1.1 Global Antitumor ADC Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antitumor ADC Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Antitumor ADC Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Antitumor ADC Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antitumor ADC Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Antitumor ADC Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antitumor ADC Drugs Sales by Application (2021-2032)
- 7.1.1 Global Antitumor ADC Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antitumor ADC Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Antitumor ADC Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Antitumor ADC Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antitumor ADC Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Antitumor ADC Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antitumor ADC Drugs Value Chain Analysis
- 8.1.1 Antitumor ADC Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antitumor ADC Drugs Production Mode & Process
- 8.2 Antitumor ADC Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antitumor ADC Drugs Distributors
- 8.2.3 Antitumor ADC Drugs Customers
9 Global Antitumor ADC Drugs Analyzing Market Dynamics
- 9.1 Antitumor ADC Drugs Industry Trends
- 9.2 Antitumor ADC Drugs Industry Drivers
- 9.3 Antitumor ADC Drugs Industry Opportunities and Challenges
- 9.4 Antitumor ADC Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst